Kipferon, vaginal and rectal suppositories 200 mg+500000 me 10 pcs

Kipferon is a complex drug form containing human recombinant interferon-α2 and a complex immunoglobulin preparation (CIP). Interferon-α2 is an activator of innate and acquired immunity; it has expressed antiviral activity, strengthens protection against viral, chlamydial, mycoplasma and bacterial infections, has an immunomodulatory effect in development of immunological reactions, promotes growth and maintenance of normal intestinal and vaginal flora.

The biological activity of interferon-α2 is realized through its interaction with the receptor apparatus of immunocompetent and other cells, resulting in increased expression of HLA I and HLA II molecules on all cell types and regulation of cell cooperation, increased activity of natural killer cells and in resistance of intact cells against their cytolytic action, proliferation of CD8 T-cells. Increases the production of gamma-interferon by natural killer cells. Complex immunoglobulin preparation KIP contains specific and non-specific immunoglobulins of classes G, M, A.

The combination of antiviral, antichlamydial, antibacterial and antitoxic antibodies belonging to different immunoglobulin classes provides agglutination, neutralization and precipitation of etiotropic pathogenic agents. In the place of application it provides stabilization of interferon from mucous membrane secretions, normalizes local immunity due to inflow of IgA and IgM with suppositories (substitution effect), increases activity of locally produced cytokines.

Indications

The drug is used in the treatment of diseases accompanied by secondary immunodeficiency states:

Active ingredient

Composition

Active substances:

immunoglobulin complex preparation (ICP) – 0.2 g,

interferon alpha-2b human,

recombinant – 500,000 IU;

Associates:

“SolPro” special purpose confectionery fat,

for chocolate products and candies – 0,838 g,

Petroleum paraffin solid P-2 – 0,085 g,

Emulsifier “Solid” (T-2) – 0,085 g,

sodium hydrophosphate dodecahydrate – 0,055mg,

Sodium dihydrophosphate dihydrate – 0,018mg,

sodium chloride – 0,110mg,

purified water – 0,012g

How to take, the dosage

Kipferon is used rectally and vaginally. The drug is used in combination with conventional means of pathogenetic therapy of infectious diseases, as well as antibiotics when indicated. The method and regimen of dosing as well as its use in complex treatment is determined by a doctor depending on the diagnosis and the severity and severity of the disease.

Acute respiratory diseases, inflammatory diseases of the oropharynx of bacterial and viral aetiology: suppositories are administered rectally (mostly after the defecation act) to children under 1 year old – one suppository a day, children under 12 years – one suppository twice a day, adults and children over 12 years – one suppository three times a day. Kipferon” is the most effective and advisable prescription in the acute phase of the disease (preferably in the first 3 days). The duration of the course of treatment is determined by the etiology, the form of severity of the disease, the presence of concomitant complications, pathological conditions and is 5-7 days.

Acute viral (rotavirus) and bacterial (salmonellosis, dysentery, coli-infection) intestinal infections, including with manifestations of intestinal dysbiosis of varying severity in children: suppositories are administered rectally (mainly after the act of defecation) to children under 1 year old one suppository per day, children under 12 years – one suppository twice a day, adults and children over 12 years – one suppository three times a day. It is most effective and expedient to prescribe the drug in the acute period of the disease (preferably in the first 3 days). Duration of the course of treatment is determined by the etiology, the form of severity of the disease, the presence of concomitant complications, pathological conditions and is 5-7 days.

Urogenital chlamydia in women (including pregnant women in the II-III trimesters of pregnancy), including vaginal dysbacteriosis, vulvovaginitis, cervicitis uteri, cervical erosion: suppositories are administered deeply intravaginally (before contact with the posterior fornix of the vagina and cervix) for 1-2 suppositories, depending on the severity of the disease, twice a day. The course of treatment averages 10 days; in the presence of cervical erosion the drug is continued until its epithelialization. Under indications the course of treatment may be repeated in one month. Treatment should begin in the first days after menstruation. Before introduction it is recommended to remove mucus from the mucous membranes of the vagina and cervix.

Special Instructions

When used in the recommended doses, the drug does not affect the behavior or functional indicators of the body, as well as does not affect the ability to operate vehicles and mechanisms.

Contraindications

Individual intolerance of individual components, pregnancy I trimester, lactation.